Frankfurt - Delayed Quote EUR

Amneal Pharmaceuticals, Inc. (2DT.F)

Compare
6.50 -0.05 (-0.76%)
At close: June 14 at 3:29 PM GMT+2
Loading Chart for 2DT.F
DELL
  • Previous Close 6.55
  • Open 6.40
  • Bid 6.35 x --
  • Ask 6.55 x --
  • Day's Range 6.40 - 6.50
  • 52 Week Range 2.32 - 6.55
  • Volume 100
  • Avg. Volume 16
  • Market Cap (intraday) 2.006B
  • Beta (5Y Monthly) 1.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.68
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.33

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

amneal.com

7,850

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2DT.F

Performance Overview: 2DT.F

Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

2DT.F
19.27%
S&P 500
13.87%

1-Year Return

2DT.F
182.61%
S&P 500
24.32%

3-Year Return

2DT.F
33.74%
S&P 500
27.88%

5-Year Return

2DT.F
2.31%
S&P 500
87.84%

Compare To: 2DT.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2DT.F

Valuation Measures

Annual
As of 6/13/2024
  • Market Cap

    2.00B

  • Enterprise Value

    4.50B

  • Trailing P/E

    93.81

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.61

  • Price/Book (mrq)

    5.21

  • Enterprise Value/Revenue

    1.95

  • Enterprise Value/EBITDA

    13.99

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.76%

  • Return on Assets (ttm)

    5.45%

  • Return on Equity (ttm)

    -165.27%

  • Revenue (ttm)

    2.5B

  • Net Income Avi to Common (ttm)

    -168.69M

  • Diluted EPS (ttm)

    -0.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    48.45M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    107.94M

Research Analysis: 2DT.F

Company Insights: 2DT.F

Research Reports: 2DT.F

People Also Watch